Puma Biotechnology, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported loss from operations was $11.8 million compared to $11.9 million a year ago. Net loss was $11.8 million compared to $11.9 million a year ago. Net loss per basic and diluted common share was $0.41 compared to $0.59 a year ago. Net cash used in operating activities was $18.5 million against $2.8 million a year ago. On Non-GAAP basis, loss from operations was $10.3 million and net loss applicable to common stock was $10.3 million, or $0.36 diluted and basic per share against loss from operations of $3.4 million and net loss applicable to common stock of $3.4 million, or $0.17 diluted and basic per share a year ago.

Puma Biotechnology, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 02:30 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Alan H. Auerbach, Founder, Chairman, Chief Executive Officer and President.

Puma Biotechnology, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2012. For the quarter, the company reported loss from operations was $22.0 million compared to $9.8 million a year ago. Net loss was $21.9 million compared to $9.9 million a year ago. Net loss per basic and diluted common share was $0.83 compared to $0.52 a year ago. The Company reported adjusted net loss applicable to common stock of $6.6 million, or $0.25 per share. Net cash used in operating activities was $24.8 million. For the year, the company reported adjusted net loss applicable to common stock was $16.8 million, or $0.77 per share. Net loss applicable to common stock for the full year was $74.3 million, or $3.42 per share compared to $10.2 million or $1.32 per share a year ago. Loss from operations was $74.4 million compared to $10.1 million a year ago. Net cash used in operating activities was $44.0 million.